Generate Biomedicines, Inc. (GENB)

NASDAQ: GENB · Real-Time Price · USD

16.28

+0.49 (3.10%)

At close: Sep 2, 2026, 4:00 PM EDT

16.32

+0.04 (0.25%)

Pre-market: Sep 3, 2026, 8:51 AM EDT

Generate Biomedicines Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	26.48	31.89	20.46
Revenue Growth	-	55.89%	-
Cost of Revenue	240.28	224.7	175.31
Gross Profit	-213.8	-192.81	-154.85
Selling, General & Admin	48.69	42.26	42.09
Operating Expenses	48.69	42.26	42.09
Operating Income	-262.49	-235.07	-196.94
Interest Expense	-0.8	-1.14	-2.12
Interest & Investment Income	13.13	13.66	18.12
Currency Exchange Gain (Loss)	-0.11	-0.15	-0.08
Other Non Operating Income (Expenses)	-0.48	-0.11	-0.15
Pretax Income	-250.73	-222.8	-181.17
Income Tax Expense	0.14	0.16	0.21
Earnings From Continuing Operations	-250.88	-222.97	-181.38
Minority Interest in Earnings	13.14	19.81	7.61
Net Income	-237.74	-203.15	-173.77
Preferred Dividends & Other Adjustments	30.93	46.37	40.01
Net Income to Common	-268.67	-249.52	-213.78
Net Income Growth	-	-	-
Shares Outstanding (Basic)	82	50	49
Shares Outstanding (Diluted)	82	50	49
Shares Change	-	2.77%	-
EPS (Basic)	-3.28	-4.98	-4.39
EPS (Diluted)	-3.28	-4.98	-4.39
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-244.35	-204.13	-121.2
Free Cash Flow Per Share	-2.98	-4.08	-2.49
Operating Margin	-991.15%	-737.04%	-962.60%
Profit Margin	-1014.51%	-782.38%	-1044.90%
Free Cash Flow Margin	-922.65%	-640.06%	-592.39%
EBITDA	-249.55	-221.89	-181.59
D&A For EBITDA	12.94	13.18	15.35
EBIT	-262.49	-235.07	-196.94

SEC Filings: 10-K · 10-Q